October 22, 2020

The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Results from a randomized placebo-controlled trial in Iran (n=59) suggest that administration of intravenous immunoglobin (IVIG) could reduce in-hospital mortality rates due to severe COVID-19. Mortality was 20% in the IVIG group (6 of 30) vs 48.3% (14 of 29) in the placebo group. Multivariate analysis showed that IVIG was associated with a reduced in-hospital mortality rate (adjusted OR = 0.003, 95% CI = 0.001-0.815).

Gharebaghi et al. (Oct 21, 2020). The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial. BMC Infectious Diseases. https://doi.org/10.1186/s12879-020-05507-4